I am a
Home I AM A Search Login

Papers of the Week


Papers: 17 Sep 2022 - 23 Sep 2022


2022 Sep 13


Lancet Neurol

Editor's Pick

Safety and efficacy of erenumab in patients with trigeminal neuralgia in Denmark: a double-blind, randomised, placebo-controlled, proof-of-concept study.

Authors

Andersen A S S, Maarbjerg S, Noory N, Heinskou T B, Forman J L, Cruccu G, Ashina M, Bendtsen L
Lancet Neurol. 2022 Sep 13.
PMID: 36113495.

Abstract

Trigeminal neuralgia is a severe facial pain disorder that is difficult to treat. Erenumab, a monoclonal antibody against the calcitonin gene-related peptide (CGRP) receptor, has proven efficacy in migraine. Erenumab modulates sensory processing in peripheral trigeminal pain pathways in mice and was reported to be effective for patients with trigeminal neuralgia in open-label studies. We aimed to evaluate the efficacy of erenumab in patients with trigeminal neuralgia.